Chemistry:Catharanthalog

From HandWiki

Catharanthalog (CAG) is a non-hallucinogenic serotonin receptor modulator of the ibogalog group related to the iboga alkaloid catharanthine but with a simplified chemical structure.[1][2] It is known to act as a serotonin 5-HT2A receptor partial agonist.[2] The drug produces analgesic-like effects in a neuropathic pain model in rodents that can be reduced by the serotonin 5-HT2A receptor antagonist ketanserin.[2] Catharanthalog is said to have relatively low blood–brain barrier permeability owing to relatively low lipophilicity.[2] It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2] The drug was first described in the scientific literature by 2025.[1][2]

See also

References

  1. ↑ 1.0 1.1 "Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives". ACS Chemical Neuroscience 16 (12): 2163–2177. June 2025. doi:10.1021/acschemneuro.5c00152. PMID 40474592. "In an oxaliplatin-induced neuropathic pain model, catharanthalog (CAG), noribogainalog (nor-IBG), and another ibogalog derivative, PNU-22394 also demonstrated consistent analgesic efficacy without observable toxicity.". 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Ibogalogs decrease neuropathic pain in mice through a mechanism involving crosstalk between 5-HT2A and mGlu2 receptors". Biomedicine & Pharmacotherapy 184. March 2025. doi:10.1016/j.biopha.2025.117887. PMID 39938347. https://flore.unifi.it/retrieve/ae8867de-6aa0-4021-8b45-37b1904e7dda/bIOMEDICINE%20%26%20PHARMACOTHERAPY%202025%20184%20117887.pdf. 





Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Catharanthalog&oldid=4038496"